title: [3-[4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding.
abstract: [3-[4-(4,5-diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) inhibits human (IC50 = 35 nM), rabbit (136 nM) and rat (1.3 microM) platelet aggregation. This compound activates adenylyl cyclase (ED50 = 6-10 nM) and stimulates GTPase in human platelet membrane preparations. The potency (EC50) of BMY 45778 stimulating adenylyl cyclase is comparable to iloprost. However, maximal stimulation of GTPase by BMY 45778 is approximately half the iloprost-stimulated activity, and BMY 45778 limits the GTPase stimulation by iloprost suggesting that BMY 45778 is a partial agonist at the IP receptor. BMY 45778 completely prevents [3H]]Iloprost binding to platelet membranes (IC50 = 7 nM). In whole platelets, BMY 45778 causes elevation of platelet cAMP levels (cAMP content doubles at 13 nM) and activation of the cAMP-dependent protein kinase (cAMP-protein kinase ratio is twice basal at 2 nM). BMY 45778 treatment of whole platelets also desensitizes the adenylyl cyclase activation by iloprost. These results indicate that BMY 45778, which is structurally different from prostacyclin and most prostacyclin agonists, acts by stimulating prostacyclin (IP) receptors.
authors.affiliation: Department of Cardiovascular, Bristol-Myers Squibb Pharmaceutical Research Institute Wallingford, CT, USA. Seiler_Steven_M.PRILVMS3@msmail.bms.com
authors.forename: S M
authors.initials: SM
authors.lastname: Seiler
authors.forename: C L
authors.initials: CL
authors.lastname: Brassard
authors.forename: M E
authors.initials: ME
authors.lastname: Federici
authors.forename: J
authors.initials: J
authors.lastname: Romine
authors.forename: N A
authors.initials: NA
authors.lastname: Meanwell
mesh_terms: D000085:Acetates / Q000494:pharmacology*; D000262:Adenylyl Cyclases / Q000187:drug effects* / Q000378:metabolism; D000818:Animals; D001667:Binding, Competitive; D002462:Cell Membrane / Q000187:drug effects / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism*; D011464:Epoprostenol / Q000819:agonists; D020558:GTP Phosphohydrolases / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D016285:Iloprost / Q000378:metabolism* / Q000494:pharmacology; D007093:Imidazoles / Q000494:pharmacology; D010080:Oxazoles / Q000494:pharmacology*; D010642:Phenoxyacetates / Q000494:pharmacology; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology*; D011494:Protein Kinases / Q000187:drug effects / Q000378:metabolism; D011817:Rabbits; D051381:Rats
chemical_list: D000085:Acetates; D007093:Imidazoles; D010080:Oxazoles; D010642:Phenoxyacetates; D010975:Platelet Aggregation Inhibitors; C080116:BMY 42393; C084677:BMY 45778; D011464:Epoprostenol; D000242:Cyclic AMP; D011494:Protein Kinases; D020558:GTP Phosphohydrolases; D000262:Adenylyl Cyclases; D016285:Iloprost; C054659:octimibate